Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine

Acta Haematologica

Volumn 101, Issue 4, 1999, Pages 173-177

  Taher, Ali ^a,b   Chamoun, F M ^b   Koussa, S ^a   Abi Saad, M ^a   Khoriaty, A I ^a   Neeman, R ^a   Mourad, F H ^b  

^a Chronic Care Center Hazmieh   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Deferiprone; Iron chelation; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON; ZINC;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; HEADACHE; HEPATITIS C VIRUS; HUMAN; MALE; MOUTH ULCER; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; RIGIDITY; SORE THROAT; THALASSEMIA; URINARY EXCRETION;

ADOLESCENT; ADULT; ARTHRALGIA; CHILD; DEFEROXAMINE; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HEPATITIS C ANTIBODIES; HUMANS; IRON; IRON CHELATING AGENTS; MALE; NAUSEA; PYRIDONES; THALASSEMIA; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 0032771863     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040949     Document Type: Article

References (24)

1. Hoffbrand AV, Wonke B: Iron chelation therapy. J Intern Med 1997;242(suppl 740):37-41.
2. Hussein MAM, Flynn DM, Green N, Hoffbrand AV: Subcutaneous and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 1976;i: 977-979.
3. Oliviery NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
4. Gabutti V, Piga A: Results of long term iron chelation therapy. Acta Haematol 1996;95:26-36.
5. Porter JB, Huehns ER: The toxic effects of desferrioxamine. Baillière's Clin Haematol 1989; 2:459-474.
6. Kontoghiorghes GJ, Goddard J, Barlett AN, Sheppard L: Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimenthyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990;48:255-261.
7. Al-Refaie FN, Wonke B, Hoffbrand AV, Wicken DG, Nortey P, Kontoghiorghes GJ: Efficacy and possible adverse effects of the oral chelator L1 in thalassemia major. Blood 1992; 80:593-599.
8. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B: Results of long term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91: 224-229.
9. Kontoghiorghes GJ, Barlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P: Long-term trial with the oral iron chelator 1,2 dimethyl-3-hydroxypyrid-4-one (L1). Iron chelation and metabolic studies. Br J Haematol 1990;76:295-300.
10. Hoffbrand AV: Oral iron chelation. Semin Haematol 1996;33:1-8.
11. Olivieri NF, Koren G, Matsui D, Blendis I, Cameron R, Fredman MH, Templeton DM, Liu PP: Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major: One-year comparison with subcutaneous desferrioxamine. Blood 1991;78(suppl I): 369a.
12. Argawal MB, Gupte SS, Viswanathan C, Ramanathan J, Desai N, Puniyani RR, Chhablani AT: Long-term assessment of efficacy and safety of L1 an oral iron chelator, in transfusion dependent thalassemia: Indian trial Br J Haematol 1992;82:460-466.
13. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for iron chelation in patients with beta-thalassemia major. Br J Haematol 1990;76:550-553.
14. Goudsmit R, Kersten MJ: Long-term treatment of transfusion hemosiderosis with the oral iron chelator L1. Drug Today 1992; 28(suppl A):133-135.
15. Hoffbrand AV, Al-Refaie F, Davis B, Sirltanakatkul N, Jackson BFA, Cochrane J, Prescott E, Wonke B: Long-term trial of deferiprone in 51 transfusion-dependent iron overload patients. Blood 1998;91:295-300.
16. Berdoukas V, Bentley P, Frost H, Schnebli HP: Toxicity of oral iron chelator L1. Lancet 1993; 341:1088.
17. Argawal MB: Oral iron chelation: A review with special emphasis on Indian work on Deferiprone (L1). Indian J Pediatr 1993;60:509-516.
18. Mehta J, Singhal S, Mehta BC: Oral iron chelator L1 and autoimmunity. Blood 1993;81: 1971-1972.
19. Castriota-Scanderberg A, Sacco M: Agranulocytosis, arthritis, systemic vasculitis in a patient receiving the oral iron chelator L1. Br J Haematol 1997;46:254-255.
20. Cohen A: A multicenter safety trial of the iron chelator Deferiprone (abstract 273). 6th International Conference on Thalassemia and the Haemoglobinopathies. Malta 1997.
21. Barlett AN, Hoffbrand AV, Kontoghiorghes GJ: Long term trial with the oral iron chelator L1. Clinical observations. Br J Haematol 1990; 76:301-304.
22. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McCelelland RA, Burt AD, Fleming KA: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-423.
23. Stella M, Pinzello G, Maggio A: Iron chelation with oral Deferiprone in patients with thalassemia (letter). N Engl J Med 1998;339:1712.
24. Wonke B, Telfer P, Hoffbrand AV: Iron chelation with oral Deferiprone in patients with thalassemia (letter). N Engl J Med 1998;339: 1712.